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Abstract 
Hip fractures in elderly patients have very high postoperative mortality rates and the 
number of hip fractures in the United States is expected to increase exponentially before 
2030. Early surgery is essential to improve outcomes, but patients on clopidogrel (Plavix) 
have a high risk for increased bleeding if surgery is performed within the usual 72 hour 
window. This paper presents literature and research addressing the dangers of delaying 
surgery versus undergoing surgery before the effects of the clopidogrel are gone. Based 
on articles published after 2006, most researchers advocated earlier surgical intervention 
than previously recommended and emphasized an individualized approached based on 
the clients’ comorbidities and susceptibilities to select postoperative complications. 
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Surgical Delay for Hip Fracture Clients and the Use of Clopidogrel: 
An Integrative Review 
While healthcare is in demand across the country, the area most in need of 
medical expertise is geriatrics. According to the United States Department of Health and 
Human Services, people over the age of 65 represented almost 13% of the United States 
population in the year 2000. By 2030, that number is expected to rise to a total of 19%, 
an unprecedented increase (Aging Statistics, n.d.). As a result, extensive research should 
be focused on preparing safe and ethical care for the growing population of elderly 
patients (Himes, 2001). 
 Medical professionals and researchers should focus their attention on common 
issues that arise due to population aging. Aging brings specific changes in the human 
body. This thesis will specifically address the issues concerning the decrease in bone 
density and an increased risk for thrombosis. Low bone density can cause pathological 
fractures in these clients and severely limit their mobility. Hip fractures, or proximal 
fractures of the femur, are the most debilitating of these fractures with a mortality rate 
that may be as high as 23% to 32% within a year after surgical repair, especially if 
surgery is delayed for any reason (Shiga, Wajima, & Ohe, 2008).  Mortalities are usually 
due to the fact that elderly patients present with a variety of comorbidities (Marks, 
Allergrant, MacKenzie, & Lane, 2003). 
 Elderly patients usually present a number of risk factors for surgical 
complications, including cardiovascular conditions. In recent years, the anticoagulant 
clopidogrel (Plavix) has been increasingly used to treat patients who have undergone a 
cardiac catheterization, stent placements, and other cardiovascular indications (Chassot, 
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Delabays, & Spahn, 2007). Clopidogrel is different than other common anticoagulants in 
that its effects on coagulation are irreversible. The manufacturers of Plavix®, Bristol 
Myers Squibb, recommend that the medication be discontinued a minimum of seven days 
prior to any surgery to allow the body to replace affected platelets with new platelets, but 
this is not specific to the needs of patients with hip fractures (Joseph, Pillai, & Bramley, 
2007).  
Orthopedic surgeons disagree over which approach is the best for hip fracture 
patients on clopidogrel. The risks of perioperative bleeding must be weighed against the 
risk of thrombosis. The risk of thrombotic complications in orthopedic surgeries is higher 
than most other types (Joseph et al., 2007). Studies have been conducted to determine 
current practices and compare patient outcomes. The purpose of this review is to examine 
current literature to determine possible means of improving patient outcome for elderly 
clients undergoing hip fracture repair while taking clopidogrel. 
Method 
 The articles included in this integrated review come from the following databases: 
Academic Search Complete, Academic One File, ProQuest Central, ScienceDirect 
College Edition, CINAHL, Health Source: Nursing/Academic, PubMed and  MEDLINE. 
Other articles were found by an internet search for scholarly resources. All articles are 
published in peer reviewed journals within the last five years. The articles consisted of 
two level III non-experiemental studies describing current practice, eight level III 
retrospective studies comparing past patients, three level II prospective cohort studies 
also comparing patints, one literature review, and one level IV letter to the editor. 
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 Issues affecting the mortality rates of patients with fractures were researched and 
the recent theme of patients on clopidogrel became apparent as a topic worth reviewing. 
The articles were chosen based on their relevance to the research question. The question 
that this thesis discusses is what is the safest protocol for patients on clopidogrel who 
need proximal femur fracture repairs? The articles discussed various aspects of the 
dilemma including when or if to stop clopidogrel, how long to postpone surgery, and 
risks associated with each action. Articles not addressing clopidogrel and orthopedic 
surgeries may be referenced but were not included in the integrative review.  
Recent Use of Clopidogrel 
 When clopidogrel was first developed, it somewhat replaced the other two 
anticoagulants in its class, ticlopidine and prasugrel, because it was more potent and had 
fewer side effects. These three medications are known as thienopyridine prodrugs and 
they deactivate platelets (Becker & Spencer, 2006). Clopidogrel is taken orally and is 
absorbed in the intestines. The drug must go through a two-step metabolism by the liver 
(Figure 1), because the agent that actually deactivates the platelets is a carboxylic acid 
  
(Yin & Miyata, 2011)  Figure 1 Clopidogrel Metabolism 
 (Giusti, Gori, Marcucci, Saracini, Vestrini, & Abbate, 2010). The active metabolite 
peaks in the blood stream in about an hour (Becker & Spencer, 2006) and binds to the 
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P2Y12 receptor of the platelet to stop the activation process involving adenosine 
diphosphate (ADP). Once the carboxylic acid has bound to the P2Y12 receptor, it 
remains there until the platelet enters the spleen to be destroyed (Giusti et al., 2010).  
The nature of clopidogrel’s mechanism of action makes the therapeutic effect of 
clopidogrel irreversible and the patient must wait until his or her body manufactures more 
platelets that have not been chemically altered by clopidogrel. Regular 75 mg doses of 
clopidogrel inhibit 40-60% of the platelets. The half- life of the metabolite is 7.7 hours 
and it takes five days for all of the metabolite to be excreted through the kidneys and 
intestines (Becker & Spencer, 2006, p. 86). Thus, special attention is required when 
taking patients off clopidogrel therapy to ensure that the effect of the medication is 
sufficiently cleared (Grujic & Martin, 2009). 
Clopidogrel usurps both ticlopidine and prasugrel based on potency (it is 100 
times more powerful than ticlopidine) and side effects. The most common side effects are 
bleeding, bruising, diarrhea, abdominal pain, and dyspepsia. Serious but less common 
side effects include thrombocytopenia, leucopenia, neutropenia, eosinophilia, thrombotic 
thrombocytopenic purpura (TTP), aplastic anemia, pancytopenia, agranulocytosis, 
granulocytopenia, anemia, serum sickness, anaphylactoid reactions, hallucinations, 
confusion, paresthesia, taste disturbances, vertigo, vasculitis, hypotension, bronchospasm, 
interstitial pneumonitis, gastric and duodenal ulcers, vomiting, constipation, pancreatitis, 
colitis, stomatitis, acute liver failure, hepatitis, Stevens Johnson syndrome, arthritis, 
myalgia, and glomerulonephritis (Plavix 75mg, 2012). Clopidogrel would be 
contraindicated in patients with hypersensitivity, severe liver impairment, and recent or 
active bleeding (Plavix 75mg, 2012). Many of the hematological side effects of 
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clopidogrel are seen more rarely and less severely than those associated with ticlopidine, 
which may be due to the fact that the metabolite of clopidogrel does not continue to 
accumulate in the blood stream like the metabolite of ticlopidine. It also offers fewer 
gastrointestinal side effects than high doses of aspirin (Becker & Spencer, 2006, p. 87).  
According to Becker and Spencer’s book (2006), Fibrinolytic and Antithrombotic 
Therapy : Theory, Practice, and Management, studies have shown that clopidogrel is 
effective in preventing acute coronary syndrome, cerebrovascular accidents, and tissue 
ischemia related to vascular disease. Clopidogrel therapy, often started with a loading 
dose of 300 mg after thromboembolitic events, is usually combined with aspirin. This 
combination was shown to improve outcomes in patients having a coronary artery stent 
placed more than ticlopidine or clopidogrel alone. Clopidogrel with aspirin reduced the 
risk of mortality by 20% in patients with unstable angina who received a loading dose 
and prolonged anticoagulant therapy (Becker & Spencer, 2006, p. 90). The use of 
clopidogrel is expected to increase due to the accumulation of research showing its 
therapeutic qualities and due to the rapidly aging population (Butt & Aspros, 2009). 
Hip Fractures 
Orthopedic surgery encompasses a vast array of corrective and preventive 
surgeries affecting the 
musculoskeletal system 
(Carmichael, 2003). Joint 
replacements, arthritis, and 
fractures are all aspects of 
orthopedics. Many of the 
Figure 2 Proximal Femur Fracture 
(Oxford Medicine Online) 
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infirmities are not immediately life-threatening and most of the risks are associated with 
the surgical implications that come about after the hip is repaired and the patient treated. 
Hip fractures are different, especially in the elderly. An extremely high rate of mortality 
with one year of surgical correction is associated with elderly patients who sustain a hip 
fracture (Shiga et al., 2008). Approximately 350,000 hip fractures occur every year in the 
United States in patients over the age of 65 and that number is expected to double by 
2050 (Sterling, 2011). With such remarkable numbers, it is important to understand 
proper treatment and secure as many positive outcomes as possible (Himes, 2001). 
Hip fractures are defined as proximal femur fractures. The femoral neck, 
trochanters, and the femoral head are all at the proximal end of the femur and considered 
part of the hip joint (Banik & Dharmarajan, 2006). Fracture can occur in several places 
(Figure 2) and the location is a factor in the type of internal fixation required. 
Subtrochanteric fractures are the least common. Blood supply to the femur comes from 
the femoral circumflex artery, but the head is specifically by the ligamentum teres. The 
ligamentum teres alone, however, is not adequate to provide blood and oxygen to the 
head of the femur. If the blood supply is interrupted due to the fracture, the head of the 
femur may become ischemic, sustaining irreversible tissue damage and increasing local 
inflammation (Banik & Dharmarajan, 2006). 
 A hip fracture is diagnosed definitively with an MRI but several assessments and 
evaluations can be performed to ascertain a probable hip fracture and complications prior 
to surgery (Banik & Dharmarajan, 2006). It is essential to obtain a thorough patient 
history, including circumstances surrounding the break, to determine if the fracture is the 
result of a disease process such as cancer or osteoporosis, if it is the result of accidental 
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trauma, or if, in some cases, it could be the result of abuse. It is also important to 
understand the patient’s level of mobility prior to the fracture so that rehabilitation goals 
can help the patient return to his or her baseline. A mental exam is also important because 
patients, especially elderly clients, may experience an acute change in cognition. Physical 
signs of a hip fracture include thigh pain when lifting the leg or palpating the femur, 
deformity, and differing limb lengths. X-rays are helpful when diagnosing hip fractures, 
but an MRI may show a fracture that was not seen on an X-ray (Banik & Dharmarajan, 
2006). After diagnosis, tests should performed to determine possible complications so 
they can be corrected before surgery if possible. According to Koval (2004), these 
“include an electrocardiogram (EKG), urinalysis, and basic blood work (complete blood 
cell count [CBC], electrolyte levels, and coagulation profile)” and more tests should be 
performed if cardiac or pulmonary risk factors are present (p. 182).  
 To minimize the possibility of complications before and after the surgery, nursing 
care should include deep vein thrombosis (DVT) propylaxis, aggressive pain 
management, and thorough skin care (Koval, 2004). If surgery cannot take place 
immediately, patients will be put on an anticoagulant that has easily reversible effects and 
can be discontinued the day before surgery (Banik & Dharmarajan, 2006) such as low 
molecular weight heparin (Lovenox) (Koval, 2004). Compression stockings or sequential 
compression devices (SCDs) should be ordered as mechanical DVT prevention and if the 
doctor has appraised the fracture as stable, the patient should be turned every two hours 
using the log-rolling method (maintaining skeletal alignment). To prevent skin 
breakdown, meticulous attention must be given to toileting needs and personal hygiene 
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(Koval, 2004). Modifiable risk factors individual to each patient should be corrected if 
possible (Banik & Dharmarajan, 2006). 
 Major risk factors for hip fractures are associated with bone density. Thin 
Caucasian women over the age of 80 are at the greatest risk.  Patients prone to falls or 
with a family history of hip fractures are at risk as well. Some of the most common risk 
factors are smoking, a sedentary lifestyle, alcohol abuse, and a poor diet (Forciea, 
Schwab, Raziano, & Lavizzo-Mourey, 2004, p. 80). Osteoporosis often causes 
pathological fractures as well (Forciea et al., 2003, p. 86) 
Surgery to correct a hip fracture is either an internal fixation or an arthroplasty. In 
an internal fixation, surgeons reduce or realign the fracture under fluoroscopic imaging 
and place screws, and plates to stabilize the fracture. At times, an open reduction is 
required, but blood loss should be minimized if possible. If the head of the femur is not 
viable – a common problem in elderly patients – an arthroplasty (or joint replacement) is 
usually required (Skinner, 2003, p. 146). If the acetabulum (the hip portion of the pelvis) 
is intact, a hemiarthroplasty is possible, replacing only the head of the femur (Skinner, 
2003, p. 394). If the fracture extends and damages the pelvis, however, a total hip 
arthroplasty is necessary (Skinner, 2003, p. 146).  
Special Considerations for Elderly Patients 
 Elderly patients are more sensitive to medications and surgical trauma than 
younger patients. Metabolic changes in the patient can alter the patient’s response to 
medications, requiring differing doses and specific interventions (Forciea et al., 2004, p. 
29). Fifty percent of clopidogrel is excreted through the kidneys (Becker & Spencer, 
2006, p. 86), but the kidneys are one of many areas that are affected by age (Forciea et 
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al., 2004, p. 29). Surgical mortality correlated directly to the age of the client as well 
(Forciea et al., 2004, p. 241). 
Clopidogrel 
 Between the age of 30 and 80 years, the kidney loses 20-25% of its mass. Stenosis 
of the renal blood vessels (considered a normal aspect of aging) leads to loss of pressure 
regulation in the kidneys which can lead to damage in the nephrons, the functional 
component of the kidney. The glomerular filtration rate (GFR), used to measure kidney 
function, decreases gradually throughout adulthood but begins to deteriorate much more 
rapidly in the later years. If the kidneys are no longer as efficient as they were, 
clopidogrel will not be excreted from the body as rapidly and the anticoagulant effect will 
remain longer. The patient’s GFR should be measured using creatinine clearance rather 
than serum creatinine alone due to the fact that elderly patients may have normal levels of 
serum creatinine but still present with kidney failure (Forciea et al., 2004, p. 29).  
 Elderly men and women also have changes in liver function which affects the way 
clopidogrel is metabolized. Because clopidogrel must be metabolized to be effective, 
decreased liver function could delay or minimize the effect of the medication. The liver 
shrinks with age and blood supply may decrease by 35-40%. This significantly affects the 
rate of drug metabolism and will both decrease the potency and prolong the effect of the 
drug (Forciea et al., 2004, p. 30). More precisely, clopidogrel’s half-life may be two to 
three times longer in elderly patients (Desager, 1994).  
Surgical Outcomes 
 The elderly population is much more likely to require surgical correction of a 
fracture. Because of common comorbidities, they are also more likely to sustain a 
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fracture. Sadly, they are more likely to develop complications or die as a result of 
surgery. The increased morbidity and mortality associated with surgery, however, is due 
to the high incidence of comorbidities in this demographic (Forciea et al., 2004, p. 241), 
so this is a vicious cycle that can only be interrupted by careful prevention of modifiable 
risk factors.  
 Comorbidities must be identified as soon as possible and treated to prevent 
complications during and after surgery. Patients with pulmonary conditions should be 
encouraged to cough and deep breathe before and after surgery. Bronchodilators may be 
indicated and prescribed to promote oxygenation (Forciea et al., 2004, p. 245). Patients 
with cardiovascular comorbidities will need special attention to thromboembolism 
prophylaxis due to reduced circulation and a possible echocardiogram to determine the 
strength of the heart before surgery (Forciea et al., 2004, p. 246). Antibiotic therapy is 
recommended due to decreased immunological function secondary to age. An important 
note must be made concerning anesthesia during the surgery:  regional or spinal 
anesthesia is generally considered the safer procedure. However, certain anticoagulants 
may cause a spinal hematoma if an epidural is performed. Therefore, based on 
coagulation studies, general anesthesia may be considered the better choice for certain 
patients at a high risk for spinal hematomas (Mercado & Petty, 2003). As mentioned 
before concerning clopidogrel, elderly patients may have a more difficult time 
metabolizing the medications used for anesthesia and sedation, requiring that they be 
closely observed (Klotz, 2009).  
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Surgical Delay 
 A clear correlation between surgical delay and morbidity has been established in 
elderly patients and the morbidities arise primarily due to prolonged immobility (Shiga et 
al., 2008). Performing early surgery to repair hip fractures decreased the hospital stay, 
decreased pressure sores (Leung, Lau, Kwan, Chow, & Kung, 2010), resulted in fewer 
cases of pneumonia (Simunovic, Devereaux, & Bhandari, 2010),  and decreased 
incidence of thromboembolitic complications (Smith, Parvizi, & Purtill, 2011). Surgical 
delay and mortality has been controversial as many of the mortalities were caused by the 
comorbidity that delayed the surgery (Vidán, Sánchez, Gracia, Marañón, Vaquero, & 
Serra, 2011). One of the main causes of descepancy, though, remains the definitely of 
early surgery versus delayed surgery (Simunovic et al., 2010). 
Length of Stay 
 According to Khan, Kalra, Khanna, Thiruvengada, and Parker (2009), not only 
does delaying surgery prolong the pain and discomfort of the injury, it most likely 
prolongs the patient’s hospital stay. Naturally, if surgery is delayed a certain number of 
days, the patient will remain in the hospital for those days, but studies have shown that 
the recovery time in the hospital is prolonged as well (Leung et al., 2010). The study 
conducted by Vidan et al. (2010) showed surgical delay longer than five days was 
associated with a longer hospital stay and Siegmeth, Gurusamy, and Parker (2005) found 
that patients stayed 10.9 days longer postoperatively if the surgery was postponed longer 
than 48 hours. Some studies have shown an increase in the length of stay with a delay of 
only 24 hours (Simunovic et al., 2011). Of the all the complications addressed in the 
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articles reviewed in this thesis, an increased hospital stay was most consistently 
correlated with surgical delay. 
Skin Integrity and Nutrition 
 Patients with a hip fracture are placed on bed rest to avoid further displacement of 
the fracture and to prevent pain. Mobilizing patients with unstable fractures before 
surgical correction is out of the question due to risk of displacement which may cause 
death in some elderly patients (Skinner, 2003, p. 146). Immobility places the body weight 
on body prominences touching the surface of the bed or mattress. Blood flow is pushed 
out of the tissues and, given enough time, will become necrotic. Skin breakdown is 
accelerated by moisture and friction. The risk of developing pressure ulcers is 
significantly decreased by mobilizing the patient, which can only be done after surgery 
(Leung et al., 2010).  
Proper nutrition is essential for healing both the surgical site and the fracture. The 
patient’s diet should be high in protein and vitamin C. Phosphorous, magnesium, and 
calcium are all essential for bone formation. Fiber and an adequate water intake are also 
essential while the operation is postponed to prevent constipation which may be a result 
of immobility and opioid analgesics (Lewis, Heitkemper, O'Brien, Dirksen, & Bucher, 
2009). While none of the studies specifically addressed this issue, both Butt and Aspros 
(2009) and Harty, McKenna, Moloney, D’Souza, and Masterson (2007) documented that 
the patients participating in the study were fasted several times only to have surgery 
cancelled the next day. This may contribute to the extended stay in the hospital as well. 
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Postoperative Pneumonia and Urinary Tract Infections 
 Surgical delay has also been associated with postoperative pneumonia and urinary 
tract infections (UTIs). A hip fracture can prevent patients from voiding as often as usual, 
allowing time for bacterial growth in the urethra. Severe pain can also cause hesitancy 
and decreased emptying of the bladder. Prevention of pneumonia centers around 
decreasing patient risk of aspiration and coughing and deep breathing. Coughing with a 
hip fracture is very painful, though, so the sooner surgery can be performed the less likely 
the patients are to contract pneumonia postoperatively (Leung et al., 2010). One study 
found that the number of patients who contracted pneumonia jumped from 12 out of 444 
after a 72-hour delay to 50 out of 550 after a 5-day delay, from 2.7% to 11.8%. The same 
study found that 45 patients developed UTIs after a surgical delay of 72 hours and that 
number rose to 65 when the patients had a 5-day delay (Vidan et al., 2011). A longer stay 
in the hospital naturally leads to a higher risk of developing a nosocomial infection, the 
two most common infections being pneumonia and UTIs (Breathnach, 2009). 
DVT and Embolism Prophylaxis 
The veins in the legs have the highest risk of developing embolisms. Deep vein 
thrombosis (DVT) results from immobility and increased platelet aggregation. Veins are 
not made up of muscles like arteries, but they rely on valves and the muscles surrounding 
them to move blood toward the heart. When a patient is lying in bed, his or her blood is 
pooling in his or her veins and beginning to coagulate. Antiembolism stockings (TED 
hose) apply about 18 mmHg of pressure to push the blood back up to the heart. 
Sequential Compression Devices are placed on a patient’s legs for the same reason. In 
addition, the patient should be repositioned frequently to encourage blood flow as well. 
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Hip fractures have been associated with an even higher risk for thrombosis (Lewis et al., 
2009).   
For patients with proximal femur fractures, anticoagulants are necessary on top of 
mechanical prevention, especially when surgery will be delayed (Skinner, 2003). In one 
study, the probability of developing an embolism rose 14.5% if surgery was delayed just 
one day and 33.3% if it was delayed longer than seven days even if the patients were on 
prophylactic anticoagulants. The same study found that all 10 of the preoperative DVTs 
were asymptomatic and not detected by a thorough physical assessment. Smith et al. 
(2011) recommend that Doppler ultrasound be part of the protocol for all hip fracture 
patients. These DVTs greatly increase the patient’s risk of postoperative 
thromboembolitic complications and indirectly increase the patient’s risk of mortality 
(Smith et al., 2011).  
Review of Research on Hip fractures and Clopidogrel 
 Because clopidogrel is a relatively new drug, almost all of the research regarding 
patients with hip fractures on clopidogrel has been conducted in the last five years. 
Clopidogrel created a dilemma for orthopedic surgeons because of its irreversible effects. 
After clopidogrel was shown to improve patient outcomes in acute coronary syndromes, 
stent placement, and DVT prophylaxis, doctors began prescribing clopidogrel more 
frequently. If the patient fell and fractured a femur while taking clopidogrel, surgery was 
often postponed for up to seven days as recommended by the manufacturers. It had been 
well established in the literature, however, that hip fracture patients should undergo 
surgery as soon as possible based on a correlation between surgical delay and morbidity 
(Shiga et al., 2008).  It was also easily established that patients on clopidogrel lost more 
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blood when surgery was performed within the usual 48 hour window (Chechik et al., 
2011). As the matter was further explored, other questions were revealed. Surgeons 
began to discuss whether oral DVT prophylaxis was required once clopidogrel was 
discontinued. There was a lack of consensus concerning type of anesthesia to use in order 
to prevent a spinal hematoma (Lavelle, Demers, & Uhl, 2007). Many physicians disagree 
on how soon to resume treatment with clopidogrel after surgery is performed (Joseph et 
al., 2007). Adding to the risk of bleeding associated with clopidogrel, abruptly stopping 
treatment causes a period of rebound hypercoagulation that further places the patient at 
risk for a thromboembolism (Collyer, Reynolds, Truyens, Kilshaw, & Corcoran, 2011).  
Orthopedic Surgeons’ Current Protocol 
 Recent research shows no protocol in place for standardizing treatment of these 
patients. Two articles were published in 2007 assessing the disagreement among 
surgeons. Joseph et al. (2007) sent a survey to 140 orthopedic consultants in Scotland, 
contacted Bristol-Myers Squibb, and consulted with four hematology departments in an 
effort to compare practice with evidenced-based recommendations. Bristol –Myers 
Squibb maintained that clopidogrel should be discontinued seven days before surgery, but 
only 47.2% of consultants stopped clopidogrel for seven days. Almost 14% did not stop 
clopidogrel for orthopedic surgeries and the remainder varied, stopping the medication 
anywhere from 5 to 21 days preoperatively. The hematology departments displayed no 
consensus regarding urgent orthopedic surgeries, but suggested that perhaps clopidogrel 
therapy could continue perioperatively as a means of thromboprophylaxis. The authors 
concluded that patients should be assessed individually to determine the appropriate 
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emergency care and suggested more research should be conducted in this area (Joseph et 
al., 2007). 
 Lavelle et al. (2007) conducted a survey as well to “attempt to ascertain the 
current standard of care among academic orthopedic centers” as it pertains to patients on 
clopidogrel who sustain a hip fracture (p. 997).  Half of the seventy-four programs that 
responded stated that they delayed surgery not more than three days for patients on 
clopidogrel, but 89% stated that surgery was not postponed at all for emergent cases. 
Several centers responded that there was no protocol, but stated that each surgeon 
determined what he or she deemed safest. The authors defined their findings as a 
“complete lack of consensus” (Lavelle et al., 2007, p. 996). 
Perioperative Blood Loss 
 Chechik et al. (2011) focused their study on perioperative blood loss and patients 
taking clopidogrel. They also narrowed their study to hip fractures over the age of 40. 
This allowed 88 patients in the study, 44 with continuous clopidogrel therapy and 44 with 
either aspirin or no anti-platelet therapy.  The purpose of the study was to determine the 
actual risk of blood loss in patients on long term clopidogrel. The amount of blood loss 
was determined both by measuring intra-operative blood loss and drainage and by pre- 
and postoperative hemoglobin levels. Patients who dropped below 9 g/dL were given a 
blood transfusion. The study showed that while blood loss was significantly higher in 
patients taking clopidogrel and combined therapy (clopidogrel and aspirin) when surgery 
was not delayed, short term mortality was unaffected. Probably due to their prior 
comorbidities, these patients did experience more cardiovascular and cerebrovascular 
complications. The authors suggest that anticoagulation therapy not be discontinued if 
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possible, but state that surgeons must determine each patient’s individual risks (Chechik 
et al., 2011). 
 Johansen, White, and Turk (2008) also focused on perioperative blood loss. This 
study of 17 clients found that patients’ hemaglobin levels fell 1.3 g/dL more if their 
surgery was not delayed. Of the ten patients whose surgeries were delayed, however, two 
experienced serious thromboembolitic complications. The authors distinguished between 
emergency, urgent, and electives surgeries, stating that emergency surgeries were 
performed immediately and elective surgeries should be performed once the effect of the 
drug has worn off, but that urgent surgeries were the cause of conflict. Based on their 
findings, the authors suggested that each patient be evaluated individually for risk of 
bleeding and risk of thrombosis to determine a time for surgery (Johansen et al., 2008). 
Overview of Research 
 Most of the remaining research aimed to determine if a correlation existed 
between patient outcomes and clopidogrel by analyzing time-to-surgery and 
postoperative complications. Several small scale studies have been conducted on this 
topic. Butt andAspros (2009) compared comorbidities, surgical delay, type of 
thromboprophylaxis, hemoglobin levels, and American Society of Anesthesiologists 
(ASA) scores (which assess patient acuity and comorbidities). They found that patients 
who underwent hip fracture repair needed more blood transfusions and had a higher 
mortality when surgery was delayed (Butt & Aspros, 2009).  
 The study Chechik, Amar, Khashan, and Kadar (2012) conducted had different 
findings regarding clopidogrel and hip fractures. The average age of the patients in this 
study was 81.6 years. Based on 30 hip fracture patients whose surgery was delayed and 
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30 patients who underwent surgery within 48, Chechik et al. found that mortality rates 
were similar but patients with delayed surgery had longer hospital stays and more 
complications related to immobility. Bleeding complications, however, were similar in 
both groups (Chechik et al., 2012). 
 One study’s results showed that there was a significant increase in acute coronary 
syndrome (ACS) that correlated with the length of time clopidogrel had been withdrawn 
(Collyer et al., 2011). This study focused on hip fracture patients over the age of 60. Out 
of 111 patients who had their clopidogrel discontinued for surgery, 23 experienced ACS 
in 4 to 8 days (Collyer et al., 2011). 
 Cox, Talbot, Topp, and Templeton (2008) focused on blood loss and hospital stay 
when studying 20 patients (average age of 81 years) from July 2005 to July 2006. They 
found that patients had lower postoperative hemoglobin when surgery was immediately 
performed, but there was no increase in postoperative complications. They also found 
that length of stay in the hospital after surgery was increased by three days on average 
when surgery was postponed seven days. Based on that information, the authors suggest 
early surgical repair. On a related topic, one of the observations the researchers reported 
was that patients who had delayed surgical intervention also more commonly had spinal 
anesthesia. The authors attribute this to the risk of a spinal hematoma if surgery is 
performed immediately (Cox et al., 2009). 
 Harty et al. (2007) found a significant increase in patient mortality when 
corrective surgery was delayed for patients on clopidogrel over the age of 65. Comparing 
21 patients on clopidogrel to 159 patients in the control group, they found that surgery 
was performed an average of 7.2 days after the fracture for patients on clopidogrel and 
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only 2.1 days for patients not on clopidogrel. Twenty-nine percent of patients on 
clopidogrel died with 30 days of operation and only 4% of patients died within 30 days in 
the control group. However, because this study did not differentiate between patients on 
clopidogrel who did get early surgery and patients on clopidogrel who had delayed 
surgery, the higher mortality could be attributed to the use of clopidogrel rather than the 
timing of the surgery. The author recommends an experienced surgeon operate and the 
patient be given platelets two hours before surgery (Harty et al., 2007). 
 Khatib, Isaacs, Walsh, Walton, and Molnar (2011) conducted a cohort study to 
“examine the bleeding risk and complication rate of hip fracture surgery without delay in 
patients who were taking clopidogrel”. The authors make the significant observation that 
hip fracture surgeries generally involve less vascular disruption than cardiothoracic 
surgeries. This is significant because the seven day delay recommended by clopidogrel 
manufacturers is based on cardiothoracic literature (Khatib et al., 2011) and therefore 
may not apply to orthopedic surgery. This study also found that age was a significant 
factor in postoperative hemoglobin levels (the average age was 84 years). The older the 
patient was, the greater the drop in hemoglobin. Surgery was not delayed based on 
clopidogrel and it appeared that it was safe to operate without delay on patients taking 
clopidogrel (Khatib et al., 2011).  
 One study analyzed the comorbidities that patients on clopidogrel had prior to 
surgery on top of assessing the outcome of delayed surgery. For these patients, surgery 
was delayed for an average of eight days and the average age was 82. Mortality and 
morbidity were higher in these patients than in the patients in the control group who were 
not on clopidogrel and had surgery in an average of 2.3 days. As a result of these 
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findings, the authors suggest having every patient assessed by an anesthetist to determine 
if general anesthesia is possible over spinal anesthesia and have platelets available in case 
a transfusion is needed (Leonidou, Cam, & Chambers, 2011). 
 Maheshwari, Acharya, Monda, and Pandey (2011) conducted research in the 
United Kingdom to determine correlation between patients over the age of 64 with hip 
fractures on clopidogrel and one-year mortality. They discontinued clopidogrel at least 
seven days before the surgery as recommended and no patients needed more than one 
blood transfusion postoperatively. Unfortunately, 10 out of 30 patients experienced 
complications related to immobility and 26% died within one year. The researchers 
recommend that surgery be performed “without undue delay” on “medically fit” patients 
because surgical delay was the only independent factor to directly correlate with 
increased mortality (Maheshwari et al., 2011). 
 Obideyi, Griffiths, and Parker (2008) wrote a short article describing their small 
scale study. The purpose of the article was to present successful cases of early surgical 
intervention for hip fracture patients on clopidogrel. Only six elderly patients (average 
age of 86) were presented and three of those had spinal anesthesia despite clopidogrel 
therapy. The patients underwent surgery in 27.8 hours on average. The authors feel that 
this type of patient should not be subjected to protocol. Rather, each case should be 
carefully considered, with early surgical intervention and spinal anesthesia being viable 
options (Obideyi et al., 2008). 
 The last retrospective article reviewed presented evidence that early surgery was a 
possible alternative for patients on clopidogrel. Gronski and Sim (2009) studied 21 
patients on clopidogrel who needed a hip fracture repair and compared them to hip 
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fracture patients who were not on clopidogrel. Of the patients on clopidogrel, five 
patients had surgery delayed longer than five days based on concern regarding the use of 
clopidogrel, which in other studies has been shown to significantly increase the risk of 
postoperative complications related to immobility. Four patients whose clopidogrel was 
held for greater than two days needed blood transplants, but the patients whose 
clopidogrel was held for less than two days (n=8) did not need any transfusions. The 
authors concluded that operating specifically within the first two to three days was 
clinically safe but stated that a larger study should be conducted to substantiate their 
claims (Gonski & Sim, 2009). 
Additional Literature 
 Haidar and Taher (2010) wrote a Letter to the Editor of Injury arguing that two to 
three days may be the safest time to surgically correct hip fractures in patients on 
clopidogrel. They based their opinion on clopidogrel’s mechanism of action and 
metabolism. According to the authors, in two to three days, patients may have regained as 
much as 20% of unaffected platelets which would be sufficient to perform surgery safely 
(Haidar & Taher, 2010). 
 Steele, Fox, Fletcher, Grigg, and Bell (2011) compiled a literature review 
describing recent practice and protocols, blood loss, risks for clopidogrel patients in 
orthopedic surgeries, and risks of holding clopidogrel before and after surgery. The 
authors recommended several strategies to prevent poor patient outcomes. Decisions 
should be made after consulting an anesthetist and the cardiologist who prescribed 
clopidogrel. Use of clopidogrel alone should not be a reason to postpone surgery and 
platelet transfusions should be available during surgery. If the patient does not have a 
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high risk for thrombotic episodes, clopidogrel may be discontinued for a short time. The 
literature review demonstrates no consensus regarding protocol and states that care must 
be individualized to the patient (Steele et al., 2011). 
 Conclusion 
 All of these studies have contributed to the body of knowledge available to 
orthopedic surgeons in order to assist them in treating hip fracture patients on clopidogrel 
in the safest way possible. Even though the use of clopidogrel is growing and hip 
fractures are becoming 
more common due to the 
aging population of the 
United States, all of the 
studies involve a small 
number of patients 
(Table 1). Thus, the 
conclusions reached in 
these articles may not 
generalize to all patients 
over 65 years old with hip fractures and on clopidogrel. Large scale, randomized 
experiments should be conducted to determine proper time to withdrawal clopidogrel, the 
safest preoperative waiting period for the elderly populations, and the adverse effects 
relating to continued clopidogrel therapy throughout the perioperative period. 
 However, based on the combined results from these studies, several 
recommendations can be implemented to help ensure positive patient outcomes. First, a 
Table 1 
Study Total 
number of 
patients 
Patients on 
Clopidogrel 
Patients in 
control groups or 
on other 
anticoagulants 
Butt & Aspros 15 15 0 
Chechik et al. 60 60 0 
Chechik et al.2 88 44 44 
Collyer et al. 1381 114 1267 
Cox et al. 20 20 0 
Harty et al. 180 21 159 
Johansen et al. 17 17 0 
Khatib et al. 338 39 299 
Leonidou et al. 405 27 378 
Maheshwari et al. 30 30 0 
Sim et al. 135 21 114 
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thorough history and physical should be performed to determine each individual client’s 
risks and comorbidities. Second, anticoagulation therapy should continue throughout the 
hospital stay even if clopidogrel is discontinued in order to prevent thromboembolitc 
complications that these patients are prone to. Third, if surgery is being performed while 
the patient is on clopidogrel or very shortly after, the patient should be prepared to 
receive a platelet transfusion if blood loss is too high and the surgery should be 
conducted by an experienced orthopedic surgeon to shorten operative time as much as 
possible. Last, at the discretion of the surgeon and interdisciplinary team, surgery should 
be performed at the earliest possible date to prevent complications of immobility and 
decrease patients 1-year mortality.  
  
CLOPIDOGREL AND SURGICAL DELAY  27 
 
References 
Aging Statistics. (n.d.). Administration on Aging. Retrieved from 
http://www.aoa.gov/aoaroot/aging_statistics/index.aspx 
Banik, P., & Dharmarajan, T. S. (2006). Hip fracture: Risk factors, preoperative 
assessment, and postoperative management. Postgraduate Medicine, 119(1), 31-
38. 
Becker, R. C., & Spencer, F. A. (2006). Fibrinolytic and antithrombotic therapy: Theory, 
practice, and management. Oxford University Press. 
Breathnach, A.S. (2009). Nosocomial infections. Medicine, 37(10), 557-561. 
Butt, U., & Aspros, D. (2009). Clopidogrel and surgical delay in patients with hip 
fractures: A district general hospital audit. Internet Journal of Orthopedic 
Surgery, 12(1), 5. 
Carmichael, J. (2003). Orthopaedic surgery. Student British Medical Journal, 11, 62-63. 
Chassot, P., Delabays, A., & Spahn, D.R. (2007). Perioperative use of anti-platelet drugs. 
Best Practice & Research Clinical Anaesthesiology, 21(2), 241-256. 
Chechik, O., Thein, R., Fichman, G., Haim, A., Tov, T., & Steinberg, E. L. (2011). The 
effect of clopidogrel and aspirin on blood loss in hip fracture surgery. Injury, 
42(11), 1277-1282. 
Chechik, O., Amar, E., Khashan, M., Kadar, A., Rosenblatt, Y., & Maman, E. (2012). In 
Support of early surgery for hip fractures sustained by elderly patients taking 
clopidogrel. Drugs & Aging, 29(1), 63-68. 
Collyer, T. C., Reynolds, H. C., Truyens, E. E., Kilshaw, L. L., & Corcoran, T. T. (2011). 
Perioperative management of clopidogrel therapy: The effects on in-hospital 
CLOPIDOGREL AND SURGICAL DELAY  28 
 
cardiac morbidity in older patients with hip fractures. BJA: The British Journal of 
Anaesthesia, 107(6), 911-915. 
Cox, G., Talbot, C., Topp, K., & Templeton, P. (2009). Clopidogrel and proximal 
femoral fractures: Does timing of surgery affect blood loss and length of 
admission? A preliminary study prior to multicenter trial. European Journal of 
Trauma and Emergency Surgery, 35(3), 291-295. 
Desager, J.P. (1994). Clinical pharmacokinetics of ticlopidine. Clinical 
Pharmacokinetics, 26, 347-355. 
Forciea, M. A., Schwab, E., Raziano, D. B., & Lavizzo-Mourey, R. (2004). Geriatric 
secrets (3rd ed.). Philadelphia, PA: Hanley & Belfus. 
Giusti, B., Gori, A., Marcucci, R., Saracini, C., Vestrini, A., & Abbate, R. (2010). Drug 
and medical device interactions: Stent thrombosis and personalizing clopidogrel 
therapy. Current Pharmacogenomics & Personalized Medicine, 8(2), 124-138. 
Gonski, P. & Sim, W. (2009). The management of patients with hip fractures who are 
taking clopidogrel. Australasian Journal of Ageing, 28(4), 194-197. 
Grujic, D., & Martin, D. (2009). Perioperative clopidogrel: Is seven days enough? 
American Surgeon, 75(10), 909-913. 
Haidar, R., & Taher, A. (2011). How long should we delay hip fracture surgery for 
elderly patients on clopidogrel?. Injury, 42(12), 1509-1510. 
Harty, J.A., McKenna, P., Moloney, D., D’Souza, L., & Masterson, E. (2007). Anti-
platelet agents and surgical delay in elderly patients with hip fractures. Journal of 
Orthopaedic Surgery, 15(3), 270-272. 
CLOPIDOGREL AND SURGICAL DELAY  29 
 
Himes, C. L. (2001). Elderly Americans. Population Bulletin, 65(4), 3-40. Retrieved 
from ABI/INFORM Global. 
“Hip fractures and dislocations.” Emergencies in Clinical Radiology. Oxford Medicine 
Online, n.d. http://emradiol.oxfordtextbookofmedicine.com/cgi/content/citation 
/1/1/med-9780199238439-div1-98/FIG79 
Johansen, A., White, J., & Turk, A. (2008). Clopidogrel therapy – Implications for hip 
fracture surgery. Injury, 39(10), 1188-1190. 
Joseph, J.J., Pillai, A., & Bramley, D. (2007). Clopidogrel in orthopaedic patients: A 
review of current practice in Scotland. Thrombosis Journal, 5(6). 
Khan, S.K., Kalra, S., Khanna, A., Thiruvengada, M.M., & Parker, M.J. (2009). Timing 
of surgery for hip fractures: A systematic review of 52 published studies 
involving 291,413 patients. Injury, 40(7), 692-697. 
Khatib, Y., Isaacs, J., Walsh, N., Walton, J., & Moinar, R. (2011). Hip fracture surgery 
and clopidogrel: Is it safe to operate without delay? Journal of Orthopaedics, 
8(1). 
Klotz, U. (2009). Pharmacokinetics and drug metabolism in the elderly. Drug 
Metabolism Reviews, 41(2), 67-76. 
Knickman, J. & Snell, E. (2002). The 2030 problem: Caring for aging baby boomers. 
Health Services Research, 37(4), 849-884. 
Koval, K. (2004). A clinical pathway for hip fractures in the elderly. Techniques in 
Orthopaedics, 19(3), 181-186. 
CLOPIDOGREL AND SURGICAL DELAY  30 
 
Lavelle, W.F., Demers Lavelle, E.A., Uhl, R. (2008). Operative delay for orthopedic 
patients on clopidogrel (Plavix): A complete lack of consensus. The Journal of 
Trauma: Injury, Infection, and Critical Care, 64(4), 996-1000. 
Leonidou, A., Cam, N.B., & Chambers, I.R. (2010). Femoral neck fractures in patients on 
clopidogrel. The effect of delaying surgery and the introduction of the new SIGN 
guidelines. The Surgeon, 9(6), 318-321. 
Leung, F., Lau, T.W., Kwan, K., Chow, S.P. & Kung, A.W.C. (2010). Does timing of 
surgery matter in fragility hip fractures? Osteoporos Int, 21(4), 529-534. 
Lewis, M. M., Heitkemper, S. L., O'Brien, P. G., Dirksen, S. R., & Bucher, L. D. (2009). 
Medical-surgical nursing – Single volume text and study guide package: 
Assessment and management of clinical problems (7th ed.). St Louis, Missouri: 
Mosby. 
Maheshwari, R., Acharya, M., Monda, M., & Pandey, R. (2011). Factors influencing 
mortality in patients on antiplatelet agents presenting with proximal femoral 
fractures. Journal of Orthopaedic Surgery, 19(3), 314-316. 
Marks, R., Allergrant, J.P., MacKenzie, C.R., & Lane, J.M. (2003). Hip fractures among 
the elderly: Causes, consequences, and control. Ageing Research Reviews, 2(1), 
57-93. 
Mercado, D.L., & Petty, B.G. (2003). Perioperative medication management. The 
Medical Clinics of North America, 87(1), 37-55. 
Obideyi, A. A., Griffiths, R. R., & Parker, M. M. (2008). Acute fractured neck of femur 
fixation in patients on clopidogrel. Anaesthesia, 63(11), 1270. 
CLOPIDOGREL AND SURGICAL DELAY  31 
 
Plavix 75mg Film-Coated Tablets - Summary of Product Characteristics (SPC). (2012). 
medicines.ie – medicines information online. Retrieved from 
http://www.medicines.ie/medicine/4235/SPC/Plavix++%28sanofi-
aventis+Bristol-Myers+Squibb+SNC%29/#CLINICAL_PRECAUTIONS 
Shiga, T., Wajima, Z., & Ohe, Y. (2008). Is operative delay associated with increased 
mortality of hip fracture patients? Systematic review, meta-analysis, and meta-
regression. Canadian Journal of Anesthesiology, 55(3), 146-154. 
Siegmeth, A.W., Gurusamy, K., & Parker, M.J. (2005). Delay to surgery prolongs 
hospital stay in patients with fractures of the proximal femur. Journal of Bone and 
Joint Surgery, 87(8), 1123-1126. 
Simunovic, N., Devereaux, P. J., & Bhandari, M. (2011). Surgery for hip fractures: Does 
surgical delay affect outcomes? Indian Journal of Orthopaedics, 45(1), 27-32. 
Skinner, H. B. (2003). Current diagnosis & treatment in orthopedics (3rd ed.). New 
York: Lange Medical Books/McGraw-Hill Medical Pub. Div. 
Smith, E., Parvizi, J., & Purtill, J. (2011). Delayed surgery for patients with femur and 
hip fractures-risk of deep venous thrombosis. Journal of Trauma, 70(6), E113-6. 
Steele, M.J., Fox, J.S., Fletcher, J.P., Grigg, L.E., & Bell, G. (2011). Clopidogrel 
dilemma for orthopedic surgeons. ANZ Journal of Surgery, 81, 774-784. 
Sterling, R. S. (2011). Gender and race/ethnicity differences in hip fracture incidence, 
morbidity, mortality, and function. Clinical Orthopaedics & Related Research, 
469(7), 1913-1918. 
CLOPIDOGREL AND SURGICAL DELAY  32 
 
Vidán, M., Sánchez, E., Gracia, Y., Marañón, E., Vaquero, J., & Serra, J. (2011). Causes 
and effects of surgical delay in patients with hip fracture: A cohort study. Annals 
of Internal Medicine, 155(4), 226-233. 
Yin, T., & Miyata, T. (2011). Pharmacogenomics of clopidogrel: Evidence and 
perspectives. Thrombosis Research, 128(4), 307-316. 
